Puma Biotechnology | PBYI - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amgen USD 6.48B 307M 2025-09
Biogen USD 1.65B 34.6M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Daiichi Sankyo JPY 439.83B 95.05B 2025-12
Esperion Therapeutics USD -29.52M 32.4M 2024-09
Exelixis USD 572.18M 7M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
Glaxosmithkline GBP 8.75B 2.92B 2025-09
Incyte USD 1.39B 118.68M 2025-12
MacroGenics USD 61.25M 88.71M 2025-09
Moderna USD 226M 583M 2025-12
Novartis USD 10.82B 695M 2025-09
Pfizer USD 3.54B 7.61B 2025-09
PTC Therapeutics USD 148.38M 39.31M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Takeda JPY 790.55B 262.97B 2025-12
TG Therapeutics USD 154.43M 20.81M 2025-12
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12